SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer therapies, particularly the WT1 polypeptide neo-epitope immunotherapy cancer vaccine poised to enter pivotal Phase 3 clinical testing in 1Q 2017 for Acute Myeloid Leukemia (AML) and in 2H 2017 for Malignant Pleural Mesothelioma (MPM). SELLAS has received orphan drug designations for AML and MPM by the US FDA and the European Medicines Agency (EMA) as well as fast track designations for AML and MPM by the US FDA. There are currently studies ongoing across various development phases for ovarian cancer (in combination with OPDIVO) as well as in multiple myeloma and further future studies are being planned.

SELLAS focuses on in-licensing drug candidates that are undergoing or have already completed initial (pre-) clinical testing and then seeks to further develop those drug candidates for commercial use. The Company's management team has a proven track record of developing drugs and cancer therapeutics throughout all stages of the product's life cycle, and the team has played key roles in bringing companies public, successfully out-licensing drug candidates, forming R&D partnerships with big pharma, and creating multiple alliances with centers of excellence.